---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000151"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:53:59.424993+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MaxCyte reports preliminary FY2024 core revenue $32.2M-$32.4M, up 8-9% YoY

## Summary
- Q4 2024 core revenue expected $8.3M–$8.5M vs $7.2M in Q4 2023.
- Full-year core revenue $32.2M–$32.4M, up 8–9% from $29.8M in FY2023.
- Cash and investments ~$190M at Dec 31, 2024, above updated guidance of $185M.
- Added six SPL customers in 2024; supported launch of first FDA-approved non-viral gene-edited cell therapy.
- Audited FY2024 results expected in March 2025.

## SEC filing metadata
- accession: 0001558370-25-000151
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/0001558370-25-000151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/mxct-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000151
- JSON: https://secwatch.observer/filing/0001558370-25-000151.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.